Thomas M R, Robinson W A, Glode L M, Dantas M E, Koeppler H, Morton N, Sutherland J
Am J Clin Oncol. 1982 Dec;5(6):611-22. doi: 10.1097/00000421-198212000-00007.
Thirteen patients with advanced (Stage III) malignant melanoma have been treated with high-dose chemotherapy (nitrogen mustard or a combination of BCNU and melphalan) combined with autologous, nonfrozen, bone marrow transplantation. Three patients (24%) achieved a complete remission and are currently alive and free of disease without further therapy at 26, 60, and 73 weeks. Five patients (38%) achieved partial remissions and five patients (38%) had no response. There was no difference in the response rate to nitrogen mustard and the BCNU-melphalan combination. Severe side effects to nitrogen mustard, however, precluded its further use in this study. The major cause of death in patients was intracerebral metastases, raising the question of prophylactic brain irradiation in future studies. Studies of the recovery rate of peripheral blood neutrophil, platelet, and peripheral blood and bone marrow CFU-C suggest that autologous bone marrow infusion may be of benefit in shortening hematopoietic recovery following intensive chemotherapy.
13例晚期（III期）恶性黑色素瘤患者接受了大剂量化疗（氮芥或卡氮芥与美法仑联合使用）并结合自体非冷冻骨髓移植。3例患者（24%）实现完全缓解，目前分别在26周、60周和73周时存活且无疾病进展，无需进一步治疗。5例患者（38%）实现部分缓解，5例患者（38%）无反应。氮芥与卡氮芥-美法仑联合用药的缓解率无差异。然而，氮芥的严重副作用使其无法在本研究中继续使用。患者的主要死亡原因是脑转移，这引发了未来研究中预防性脑照射的问题。对外周血中性粒细胞、血小板以及外周血和骨髓集落形成单位（CFU-C）恢复率的研究表明，自体骨髓输注可能有助于缩短强化化疗后的造血恢复时间。
